AstraZeneca

News

AstraZeneca spins out biotech to focus on autoimmune candida...

AstraZeneca’s biologics division MedImmune is to spin out a new standalone biotech to develop six early-stage inflammation and autoimmunity programmes.

News

Tesaro and Roche to combine drugs in bladder cancer trials

Tesaro is to combine its PARP-inhibitor drug Zejula with Roche’s PD-L1 immunotherapy Tecentriq in clinical trials for metastatic bladder cancer.

Partner Content

Partner Content

£500 special discount for Drug Discovery conference in 4 wee...

Drug Discovery Conference

News

AZ signs kidney drug deal with Ionis for up to $330m

Deal is result of six-year collaboration with AZ

News

Groundbreaking lung cancer approval a big boost for AZ's Imf...

AstraZeneca’s immunotherapy Imfinzi has gained US approval in an important new earlier treatment setting for lung cancer patients.

News

Closeup of X-ray photography of human brain

Doubts over BACE drugs after Merck ends Alzheimer's trial

Decision comes a year after Merck axed EPOCH verubecestat trial

AstraZeneca spins out biotech to focus on autoimmune candida...

Tesaro and Roche to combine drugs in bladder cancer trials

£500 special discount for Drug Discovery conference in 4 wee...

AZ signs kidney drug deal with Ionis for up to $330m

Groundbreaking lung cancer approval a big boost for AZ's Imf...

Doubts over BACE drugs after Merck ends Alzheimer's trial

EU clears first drug therapy for rare disease cALD

Discover a new era of healthcare panel engagement: Grounded ...

AstraZeneca

Editor's Picks